Retsevmo ® ▼ (selpercatinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

What is the incidence of dry mouth using Retsevmo® ▼ (selpercatinib)?

Although xerostomia was the most frequent AE in the trial, there were very few dose modifications and no discontinuations due to dry mouth.

LIBRETTO-001 Clinical Trial

LIBRETTO-001 is a multicenter, open-label, phase 1/2 study of selpercatinib administered orally to patients with RET fusion-positive solid tumors, RET-mutant MTC, and other tumors with RET activation.1-4

Overall Occurrence of Dry Mouth

Dry mouth was the most common AE reported in the overall population in the LIBRETTO-001 trial (N = 746) with 300 patients (40%) reporting the event.2,5 Severity of the events was grade 1 (89%) and grade 2 (11%).5

Dry mouth occurred more often in the NSCLC cohort (43%) compared to the MTC cohort (39%).5

Selpercatinib-Related Dry Mouth

Selpercatinib-related dry mouth was reported in 265 patients (36%). Drug-related dry mouth occurred more frequently in the NSCLC cohort (40%) compared to the MTC cohort (33%).5

Dosage Modification

Selpercatinib-related dose modifications in the overall population (N = 746) included 2 patients having a drug interruption and 6 patients having a dose reduction due to dry mouth.5

No patients discontinued selpercatinib due to dry mouth.5

Concomitant Local Oral Treatment

As of data cut-off December 2019, 110 (16%) patients used a concomitant local oral treatment (Table 1). There were 53 (8%) patients that reported ‘other’ unspecified products used.5

Table 1. Concomitant Local Oral Treatments Reported in LIBRETTO-001ab5

Lidocaine hydrochloride, lidocaine

Magic mouthwash formulation

Sodium chloride


Benzydamine hydrochloride

Sodium gualenate hydrate



Calcium lactate with glucose oxidase

Aluminum hydroxide with diphenhydramine

Glucose oxidase with lactoferrin



First BLM

Glycol thymoline


a Names of products are written as reported.

b Data cut-off December 2019.

Treatment Guidelines for Dry Mouth

Lilly is unable to provide treatment guidelines or recommendations. Table 2 provides a sampling of resources that may provide helpful information for management of dry mouth. Common themes found on these websites include the importance of

  • regular dental visits

  • frequent teeth brushing and flossing, and

  • staying hydrated.

Other information regarding management of dry mouth including nutrition, diet, and artificial saliva is also available on these sites.6-10

Table 2. Internet Resources for Management of Dry Mouth6-10







a Lilly does not promote or recommend 1 website over another.


1. Phase 1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). identifier: NCT03157128. Updated July 2, 2020. Accessed January 25, 2020.

2. Retsevmo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835.

4. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383(9):813-824.

5. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

6. Dry mouth (xerostomia). OncoLink. Published February 7, 2020. Accessed March 10, 2020.

7. Weaver CH. Dry mouth or xerostomia. Cancer.Net. Published May 2018. Accessed March 10, 2020.

8. Dry mouth-xerostomia. CancerConnect. Published March 18, 2019. Accessed March 10, 2020.

9. Dry mouth. Chemocare. Accessed March 10, 2020.

10. The importance of dental health. CancerCare. Published March 17, 2016. Accessed March 10, 2020.


AE = adverse event

Lilly = Eli Lilly and Company

MTC = medullary thyroid cancer

NSCLC = non-small cell lung cancer

RET = rearranged during transfection

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 21 January 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request